Abstract: A torque limiting coupling contains a first shaft, a second shaft and a coupling ring. The coupling ring contains a coupling sleeve with an inner surface and an outer surface. The coupling sleeve is arranged in the radial direction between the first shaft and the second shaft, such that the inner surface is in frictional contact with the first shaft and the outer surface is in frictional contact with the second shaft. The coupling sleeve is double-walled with an internal annular pressure oil chamber, configured in such a way, that the coupling sleeve increases its radial thickness when the oil chamber is filled with pressurized oil and thereby increases the pressure forces and thereby the friction between the surfaces and the shafts in order to allow torque transfer between the two shafts, and that the coupling sleeve transfers no torque, when the oil chamber is not filled with pressurized oil.

Abstract: A torque limiting coupling has a shaft, a shear plate fixedly connected to the shaft, and a coaxially disposed coupling ring. The coupling ring has a lateral surface in contact with the shaft and a double-walled section with an internal annular pressure fluid chamber. When the fluid chamber is filled with pressurized fluid, the radial thickness increases and increases the pressure and friction forces for a torque transfer between the coupling ring and the shaft. A shear tube closes the pressurized fluid chamber. A shear plate is configured to cut off a tip of the shear tube in order to open the pressure fluid chamber when the first shaft slips relative to the coupling ring. A central bolt affixes the shear plate to the shaft by pressing a conical bushing of the shear plate onto a conical connector of the shaft.

Abstract: The present invention provides compositions and methods for utilizing a large capacity cloning vector (e.g., BAC) to carry a large exogenous genomic DNA (about 10-300 kb) flanked by a proximal and distal regions (10 kb) to efficiently insert into the genome of a cell in a CRISPR/Cas9-stimulated homologous recombination. Methods and compositions for microinjecting a large human gene into a mouse zygote to prepare a genetically modified mouse are also provided.

Abstract: The present disclosure is directed to chemically-stable and pharmaceutically acceptable sildenafil oral spray formulations for the treatment of diseases such as pulmonary arterial hypertension and/or SSRI-induced sexual dysfunction, wherein the oral spray formulation has a pH of about 1.5 to less than 3.0. The present disclosure is also directed to methods for treating diseases such as pulmonary arterial hypertension and/or SSRI-induced sexual dysfunction.

Abstract: The present disclosure is directed to chemically-stable and pharmaceutically acceptable sildenafil oral spray formulations for the treatment of diseases such as pulmonary arterial hypertension and/or SSRI-induced sexual dysfunction, wherein the oral spray formulation has a pH of about 1.5 to less than 3.0. The present disclosure is also directed to methods for treating diseases such as pulmonary arterial hypertension and/or SSRI-induced sexual dysfunction.

Abstract: The present disclosure is directed to chemically-stable and pharmaceutically-acceptable sildenafil oral spray formulations for the treatment of male erectile dysfunction, wherein the oral spray formulation has a pH of about 1.5 to less than 3.0. The present disclosure is also directed to methods for treating male erectile dysfunction.

Abstract: Compositions of zolpidem, and methods for their manufacture and use for treating insomnia. The compositions are formulated as oral sprays for transmucosal absorption of zolpidem. The methods of treatment in some cases involve night-time dosing administration to achieve therapeutic zolpidem blood levels within 20 minutes or less, tapering off to less than 20 ng/ml within less than five hours, in some cases less than four hours, post dosing.

Abstract: Compositions of zolpidem, and methods for their manufacture and use for treating insomnia. The compositions are formulated as oral sprays for transmucosal absorption of zolpidem. The methods of treatment in some cases involve night-time dosing administration to achieve therapeutic zolpidem blood levels within 20 minutes or less, tapering off to less than 20 ng/ml within less than five hours, in some cases less than four hours, post dosing.

Abstract: A method for producing a single-clad or multiple-clad product includes providing a welded assembly comprising a cladding material disposed on a substrate material. Both the substrate material and the cladding material are individually selected alloys. At least a first edge of the cladding material of the welded assembly does not extend to a first edge of the substrate material and thereby provides a margin between the first edges. A material that is an alloy having hot strength greater than the cladding material is within the margin and adjacent the first edge of the cladding material. The welded assembly is hot rolled to provide a hot rolled band, and the material within the margin inhibits the cladding material from spreading beyond the edge of the substrate material during the hot rolling. In certain embodiments of the methods, the substrate material is stainless steel and the cladding material is nickel or a nickel alloy.